MED1’s involvement in estrogen resistance mechanisms has been demonstrated, where silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant both in vitro and in vivo [31]. The gene discussed is MED1; the disease is breast cancer.